Your browser doesn't support javascript.
loading
Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.
Ngo, Dat; Tinajero, Jose; Li, Shanpeng; Palmer, Joycelynne; Pourhassan, Hoda; Aribi, Ahmed; Nakamura, Ryotaro; Stein, Anthony; Marcucci, Guido; Salhotra, Amandeep; Sandhu, Karamjeet; Pullarkat, Vinod; Ball, Brian; Koller, Paul.
Afiliación
  • Ngo D; Department of Pharmacy, City of Hope, Duarte, California, USA.
  • Tinajero J; Department of Pharmacy, City of Hope, Duarte, California, USA.
  • Li S; Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope, Duarte, California, USA.
  • Palmer J; Department of Computational and Quantitative Medicine, Division of Biostatistics, City of Hope, Duarte, California, USA.
  • Pourhassan H; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Aribi A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Nakamura R; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Stein A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Marcucci G; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Salhotra A; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Sandhu K; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Pullarkat V; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Ball B; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
  • Koller P; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Leuk Lymphoma ; 65(3): 372-377, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38164785
ABSTRACT
Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35-298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazinas / Sulfonamidas / Leucemia Mieloide Aguda / Compuestos Bicíclicos Heterocíclicos con Puentes / Tirosina Quinasa 3 Similar a fms / Compuestos de Anilina Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Pirazinas / Sulfonamidas / Leucemia Mieloide Aguda / Compuestos Bicíclicos Heterocíclicos con Puentes / Tirosina Quinasa 3 Similar a fms / Compuestos de Anilina Tipo de estudio: Diagnostic_studies Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos